Milestone Scientific (MLSS) Aperçu de l'action
Milestone Scientific Inc. est une société de technologie biomédicale qui brevette, conçoit, développe et commercialise des technologies d'injection diagnostique et thérapeutique, ainsi que des dispositifs à usage médical et dentaire aux États-Unis, en Chine et dans le monde entier. Plus de détails
| Score flocon de neige | |
|---|---|
| Évaluation | 0/6 |
| Croissance future | 1/6 |
| Performances passées | 0/6 |
| Santé financière | 5/6 |
| Dividendes | 0/6 |
Récompenses
Analyse des risques
MLSS Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Milestone Scientific Inc. Concurrents
Historique des prix et performances
| Historique des cours de bourse | |
|---|---|
| Prix actuel de l'action | US$0.32 |
| Plus haut sur 52 semaines | US$0.73 |
| Plus bas sur 52 semaines | US$0.22 |
| Bêta | 1.02 |
| Variation sur 1 mois | -17.24% |
| Variation sur 3 mois | 11.22% |
| Variation sur 1 an | -49.68% |
| Variation sur 3 ans | -63.18% |
| Variation sur 5 ans | -86.31% |
| Évolution depuis l'introduction en bourse | -97.75% |
Nouvelles et mises à jour récentes
MLSS: Expanding Clinical Adoption And New Capital Raise Will Drive Upside
Analysts have maintained their $1.00 price target for Milestone Scientific, noting only minor adjustments to the discount rate, profit margin assumptions, and future P/E inputs, rather than any broad change in outlook. What's in the News Reaffirmed earnings guidance for 2026, with expected revenue in the range of US$9.8 million to US$10.2 million, citing double digit growth driven by commercial adoption across dental and medical segments.MLSS: Medical Adoption And New Capital Raise Will Support Future Upside
Analysts have adjusted their price target on Milestone Scientific to $1.00, supported by updated assumptions that include a slightly lower discount rate, revised revenue growth and profit margin expectations, and a higher future P/E multiple. What's in the News Reaffirmed earnings guidance for 2026, with expected revenue of US$9.8 million to US$10.2 million, tied to commercial adoption in both dental and medical segments (Corporate Guidance).Recent updates
MLSS: Expanding Clinical Adoption And New Capital Raise Will Drive Upside
Analysts have maintained their $1.00 price target for Milestone Scientific, noting only minor adjustments to the discount rate, profit margin assumptions, and future P/E inputs, rather than any broad change in outlook. What's in the News Reaffirmed earnings guidance for 2026, with expected revenue in the range of US$9.8 million to US$10.2 million, citing double digit growth driven by commercial adoption across dental and medical segments.MLSS: Medical Adoption And New Capital Raise Will Support Future Upside
Analysts have adjusted their price target on Milestone Scientific to $1.00, supported by updated assumptions that include a slightly lower discount rate, revised revenue growth and profit margin expectations, and a higher future P/E multiple. What's in the News Reaffirmed earnings guidance for 2026, with expected revenue of US$9.8 million to US$10.2 million, tied to commercial adoption in both dental and medical segments (Corporate Guidance).MLSS: Expanded Share Authorization And Private Placement Will Support Future Upside
Milestone Scientific's analyst price target has been adjusted slightly, with analysts pointing to small refinements in the discount rate, long term profit margin assumptions and future P/E expectations as key drivers of the updated valuation. What's in the News Entered a securities purchase agreement for a private placement of 7,962,963 units at $0.27 per unit, for gross proceeds of about $2.15m.MLSS: Expanded Share Authorization Will Support Future Upside As Guidance And PE Strengthen
Analysts have adjusted their price target on Milestone Scientific to reflect a modest change in the assumed discount rate and profit margin. They are keeping fair value at $1.00 while updating their future P/E outlook to 72.06x based on the latest inputs.MLSS: Expanded Share Authorization Will Support Future Upside As Revenue Guidance Strengthens
Analysts have modestly adjusted their price target on Milestone Scientific to reflect updated views on slightly different revenue growth expectations, profit margin assumptions and a revised forward P/E profile, while keeping the fair value estimate broadly aligned with prior levels in dollar terms. What's in the News Management issued earnings guidance for the year ending December 31, 2026, with expected total revenue in a range of US$9.8 million to US$10.2 million, citing broadening commercial adoption in both dental and medical segments (company guidance).MLSS: Expanded Share Authorization Will Support Future Upside From Current Levels
Analysts have modestly adjusted their price target on Milestone Scientific to reflect updated views on discount rates, profit margins, and future P/E expectations, while keeping the fair value estimate unchanged at $1.00 per share. What's in the News The company filed a Certificate of Amendment to its Restated Certificate of Incorporation in Delaware on March 10, 2026, increasing authorized common stock from 100,000,000 to 125,000,000 (Key Developments).MLSS: Shares Will Likely Rise As Expanded Authorization Supports Undervaluation
Analysts have modestly raised their price target on Milestone Scientific to $1.00. The change reflects slightly higher assumed discount rates and price-to-earnings expectations, along with a marginally lower profit margin outlook in their updated models.MLSS: Shares Will Likely Rise As Share Authorization Supports Undervaluation
Analysts have nudged their price target on Milestone Scientific slightly higher to $1.00, reflecting small tweaks to the discount rate, profit margin assumptions, and future P/E inputs in their models. What's in the News Shareholders ratified the appointment of CBIZCPA P.C. as Milestone Scientific Inc.'s independent auditors for the fiscal year ending December 31, 2025, at the AGM held on December 18, 2025 (Key Developments).MLSS: Shares Will Likely Rise As Increased Share Authorization Supports Undervaluation
Analysts have adjusted their price target on Milestone Scientific to align with updated assumptions around discount rates, profit margins, and future P/E expectations. This has led to a modest shift in the projected valuation range expressed in US$ terms.MLSS: Shares Will Likely Rise As Auditor Approval Supports Undervaluation
Analysts have slightly lifted their price target on Milestone Scientific to around US$1.00, citing small tweaks to their discount rate, profit margin outlook, and a projected future P/E of about 71x as the main drivers of the updated view. What's in the News Shareholders approved CBIZCPA P.C. as Milestone Scientific Inc.'s independent auditor for the fiscal year ending December 31, 2025, at the AGM held on December 18, 2025 (AGM filing).MLSS: Shares Will Likely Rise As Listing Plan Supports Undervaluation
Analysts have made a modest adjustment to their price target on Milestone Scientific, keeping fair value anchored at US$1.00 while fine tuning assumptions around discount rate, revenue growth, profit margin and future P/E to reflect updated views on the company’s risk profile and earnings power. What's in the News At the December 18, 2025 AGM, shareholders approved an amendment to Milestone Scientific's Restated Certificate of Incorporation to increase authorized common shares from 100,000,000 to 125,000,000 (AGM filing).MLSS: Shares Will Likely Rise As Listing Compliance Risks Ease
Analysts have modestly increased their price target on Milestone Scientific to reflect a slightly lower perceived risk in future cash flows, despite trimming long term profit margin assumptions and applying a higher forward earnings multiple. What's in the News Proposed amendment to the Restated Certificate of Incorporation to increase authorized common shares from 100 million to 125 million, expanding potential equity financing capacity (company filing).MLSS: Shares Will Likely Rebound As NYSE Compliance Plan Progresses
Analysts have trimmed their price target on Milestone Scientific from 1.13 dollars to 1.00 dollars, citing slightly slower expected revenue growth and a modestly lower valuation multiple. This is partially offset by stable profit margin assumptions and a marginally reduced discount rate.MLSS: Shares Will Face Key NYSE American Compliance Decision by 2027
Analysts have revised their price target for Milestone Scientific downward from $1.63 to $1.13. They cite lower projected revenue growth and a higher discount rate as key factors influencing their updated outlook.CompuFlo Epidural System Will Unlock New Global Opportunities
The downward revision in Milestone Scientific’s price target reflects materially lower revenue growth expectations, leading to a drop in projected fair value from $2.12 to $1.62. What's in the News Eric C.
CompuFlo Epidural System Will Unlock New Global Opportunities
Strategic partnerships and regulatory approvals are expanding market access for the CompuFlo Epidural System, potentially driving significant revenue growth.Rendement pour les actionnaires
| MLSS | US Medical Equipment | US Marché | |
|---|---|---|---|
| 7D | -3.0% | 3.9% | -2.5% |
| 1Y | -49.7% | -19.9% | 19.0% |
Rendement vs Industrie: MLSS a sous-performé le secteur US Medical Equipment qui a rapporté -19.9 % au cours de l'année écoulée.
Rendement vs marché: MLSS a sous-performé le marché US qui a rapporté 19 % au cours de l'année écoulée.
Volatilité des prix
| MLSS volatility | |
|---|---|
| MLSS Average Weekly Movement | 14.1% |
| Medical Equipment Industry Average Movement | 8.7% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
Cours de l'action stable: Le cours de l'action de MLSS a été volatil au cours des 3 derniers mois par rapport au marché US.
Volatilité au fil du temps: La volatilité hebdomadaire de MLSS ( 14% ) est restée stable au cours de l'année écoulée, mais reste supérieure à 75 % des actions de US.
À propos de l'entreprise
| Fondée | Salariés | PDG | Site web |
|---|---|---|---|
| 1989 | 15 | Eric Hines | www.milestonescientific.com |
Milestone Scientific Inc. est une société de technologie biomédicale qui brevette, conçoit, développe et commercialise des technologies d'injection diagnostique et thérapeutique, ainsi que des dispositifs à usage médical et dentaire aux États-Unis, en Chine et dans le monde entier. Elle exerce ses activités dans les secteurs dentaire et médical. La société propose The Wand, une pièce à main jetable à usage unique pour les procédures dentaires nécessitant une anesthésie locale, sous les noms de CompuDent et STA Single Tooth Anesthesia System (système d'anesthésie à dent unique).
Milestone Scientific Inc. Résumé des fondamentaux
| MLSS statistiques fondamentales | |
|---|---|
| Capitalisation boursière | US$28.16m |
| Bénéfices(TTM) | -US$4.57m |
| Recettes(TTM) | US$8.90m |
Le site MLSS est-il surévalué ?
Voir Juste valeur et analyse de l'évaluationBénéfices et recettes
| MLSS compte de résultat (TTM) | |
|---|---|
| Recettes | US$8.90m |
| Coût des recettes | US$2.58m |
| Marge brute | US$6.32m |
| Autres dépenses | US$10.89m |
| Les revenus | -US$4.57m |
Derniers bénéfices déclarés
Mar 31, 2026
Prochaine date de publication des résultats
s/o
| Résultat par action (EPS) | -0.052 |
| Marge brute | 71.03% |
| Marge bénéficiaire nette | -51.30% |
| Ratio dettes/capitaux propres | 35.0% |
Quelles ont été les performances à long terme de MLSS?
Voir les performances historiques et les comparaisonsAnalyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/06/29 01:05 |
| Cours de l'action en fin de journée | 2026/06/29 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d'analyse utilisé pour générer ce rapport sont disponibles sur notre page Github, nous proposons également des guides pour apprendre à utiliser nos rapports et des tutoriels sur YouTube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Milestone Scientific Inc. est couverte par 3 analystes. 2 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Bruce Jackson | Benchmark Company |
| Anthony Vendetti | Maxim Group |
| James Terwilliger | Northland Capital Markets |